Metubine Iodide

NDA 6632, held by Lilly. Metocurine Iodide.

As of Nov 13, 2026, NDA 6632 (Metubine Iodide), held by Lilly, was first approved by FDA on Jan 4, 1949, with 6 approved supplements and 0 published complete response letters.

First approved: Jan 4, 1949
Review: Standard
Supplements approved: 6
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 7 submissions below

Date	Submission	Status	Documents
Jan 4, 1949	Original applicationNew molecular entity · Standard review	Approved	None posted

Products

1 strengths and forms

Product	Active ingredient	Marketing
Metubine Iodide2MG/ML · injectable;injection	Metocurine Iodide	Discontinued

All 7 submissions, including labeling and manufacturing supplements


Sep 17, 2001	Supplement 13Labeling	Approved	None posted
Sep 17, 2001	Supplement 16Labeling · Standard review	Approved	None posted
Jul 14, 1987	Supplement 11Labeling	Approved	None posted
Apr 14, 1981	Supplement 6Labeling	Approved	None posted
Nov 3, 1975	Supplement 5Labeling	Approved	None posted
Jul 1, 1974	Supplement 4Labeling	Approved	None posted
Jan 4, 1949	Original applicationNew molecular entity · Standard review	Approved	None posted

Identifiers

Application: NDA 6632
Drugs@FDA: Overview at FDA
Company: Lilly

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters